INDGN · Indegene Ltd · Business Services
INDGN · Indegene Ltd · Business Services
As of 05 Nov close
52-week range
3.9% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹1,063 Cr
Revenue YoY
PAT YoY
-0.2%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
9
P/S (TTM)
3.7
Sector P/E
42
Dividend yield
+0.4%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| INDGN (this stock) | 31.4 | 9 | +10.5% | +12.8% | 0.05 | +0.4% |
| Delhivery | 374.4 | 4.4 | +0.8% | +1.0% | 0.15 | 0.0% |
| Urban Company | Not available from data source | 11.5 | -19.4% | -15.6% | 0.06 | 0.0% |
| BLS International Services | 14.2 | 3.9 | +24.1% | +32.7% | 13.29 | +0.9% |
Promoter
Not available from data source
FII
falling 2q
MF
5.28% (+0.58pp)
rising 3q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 10 Jun 2026 | Shouvanik Chatterjee | SELL | 34,000 | ₹1.79 Cr |
| 19 Mar 2026 | Anita Nair | BUY | 22,230 | ₹99.98 lakh |
| 25 Feb 2026 | Sameer Narendrakumar Lal | SELL | 60,000 | ₹2.92 Cr |
| 14 Nov 2025 | Sameer Narendra Lal | SELL | 10,000 | ₹51.26 lakh |
| 13 Nov 2025 | BINA PATIL | SELL | 13,570 | ₹69.85 lakh |
| 11 Nov 2025 | BINA SANJEEV PATIL | SELL | 5,930 | ₹31.07 lakh |
| 10 Nov 2025 | BINA PATIL | SELL | 5,930 | ₹31.05 lakh |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-10-08 | INDGN | 2018426 | 1 | WEAK | BULK |
News timeline
- lowthehindubusinessline.com· 17 Oct 2026, 09:45 pmMovers & Shakers: Stocks that will see action this week
Concalls & investor presentations
AI-generatedKey takeaway: Indegene Limited held its Q1 FY27 earnings conference call on July 31, 2026, where management discussed the company's performance and industry trends. Management reported that the global pharma industry showed resilient growth, with the top 20 pharma companies achieving 10% to 12% revenue growth year-on-year. Indegene's Q1 revenues reached INR 10,631 million, reflecting a 39.7% year-on-year increase. The active client base grew to 105, with significant contributions from accounts beyond the top 20. Management highlighted strong deal momentum, including several contracts in the $1 million to $5 million range. The company emphasized its unique position as an embedded revenue partner with deep domain expertise and a focus on AI-driven solutions. Financially, EBITDA was reported at INR 1,795 million, with a margin of 16.9%. Management reiterated confidence in achieving margin recovery and continued growth throughout FY27.
Management highlighted strong growth and positive deal momentum in the earnings conference call.
Sourced from an exchange-filed transcript, dated 06 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Indegene Limited reported its financial results for the quarter ended June 30, 2026, highlighting a revenue from operations of ₹10,631 million, which represents a 39.7% year-over-year increase. The EBITDA stood at ₹1,795 million, reflecting a margin of 16.9%, while the profit after tax (PAT) was ₹1,162 million, with a PAT margin of 10.9%. The company expanded its active client base to 105, a 50% increase from the previous year. Management noted significant growth in revenue from top accounts and emphasized the importance of deepening client relationships. The presentation also discussed the company's focus on GenAI-powered technologies and the development of differentiated products to enhance growth. Overall, the document conveyed a strong performance in Q1 FY27, with improvements in productivity and profitability metrics.
Management emphasized significant growth and improvements in client relationships and profitability.
Sourced from an exchange-filed presentation, dated 30 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Indegene Limited reported significant milestones in its Q4 and FY26 earnings conference call, with revenues surpassing ₹1,000 crores for the first time in Q4 and exceeding ₹3,500 crores for the full year, reflecting a growth of 23.6% in INR terms. Management highlighted strategic deepening with top customers, including a significant engagement with a major client in Germany. The company expanded its active customer base and saw a notable increase in clients generating over $1 million in annual revenue. Indegene emphasized its focus on AI-led solutions, showcasing several successful projects that leverage its domain expertise. The CFO noted a strong cash position and proposed a final dividend of ₹2.25 per share, up from ₹2.00 the previous year. Management expressed confidence in future growth, citing a robust pipeline and the successful integration of recent acquisitions. The tone of the discussion was optimistic, reflecting the company's achievements and strategic direction.
Management emphasized significant growth milestones and strategic advancements.
Sourced from an exchange-filed transcript, dated 06 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item); Default / Covenant Breach (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
The company received a final order from DGSTO-1 with a demand of ₹2 dated 30 October 2023, which was remitted on 31 October 2023.
Default / Covenant Breach
2 occurrencesRecent (last 12 months)
The company has undisputed statutory dues under various tax acts (Income Tax, etc.) that are in arrears for more than six months, with amounts totaling Rs. 26.96 million pending resolution in various forums.
Earlier (1-3 years ago)
The company had delays in depositing provident fund dues ranging from 15 to 682 days. However, as of 31 March 2024, no statutory dues for more than six months were in arrears, except for disputed income tax amounts of 1.52 million and 6.96 million related to AY 2018-19 and AY 2022-23, respectively.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has a contingent liability related to a transfer pricing adjustment proposal of ₹ 1,114 million for the Assessment Year 2023-24, with the final tax demand pending.
Earlier (1-3 years ago)
Indegene Inc. is involved in a civil lawsuit in New Jersey related to alleged TCPA violations, seeking damages of USD 500 per violation or treble damages of USD 1,500 if deemed wilful, with the case under discovery proceedings as of 31 March 2025.
The company has a contingent liability related to a bank guarantee issued by the bank in favour of a government department as of 31 March 2024.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company had significant related party transactions with entities like Indegene, Inc., DT Associates Research and Consulting Services Ltd, Trilogy Writing & Consulting GmbH, and others during the years ended 31 March 2026 and 2025, including revenue from operations, expenses paid on behalf of subsidiaries, and consultancy expenses.
Earlier (1-3 years ago)
The company has transactions with related parties including Exeevo Inc and its subsidiaries, and key management personnel, involving short-term benefits and expense reimbursements for the years ended 31 March 2025 and 2024.
Statutory dues in dispute
1 occurrenceEarlier (1-3 years ago)
The company has statutory dues of 1.52 million under the Income Tax Act, 1961 related to a Transfer Pricing matter for AY 2018-19, with the dispute pending in the High Court.